Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

NCT03139851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Cyclophosphamide 50mg
DRUG: Pembrolizumab 100 MG in 4 ML Injection

Sponsor

Centre Leon Berard

Collaborators

[object Object]